Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.
Published in TZ Latest News 12 September, 2017 by The TZ Newswire Staff
Sage Therapeutics Gets a Dunce Hat
Published in TZ Latest News 12 September, 2017 by The TZ Newswire Staff
Sage Therapeutics Gets a Dunce Hat
Sage Therapeutics saw its shares drop by about a quarter early on Tuesday after the firm gave an update on its late-stage study trial in the treatment super-refractory status epilepticus.